Yuan Han

An Engineering‐Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple‐Negative Breast Cancer Immunotherapy

ABSTRACT The clinical response to immunotherapy in triple‐negative breast cancer (TNBC) is often limited by the immunosuppressive microenvironment, immune cell exhaustion, and multidrug resistance. Through a high‐throughput screen of 2,500 FDA‐approved drugs using a three‐dimensi...